BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2002806)

  • 1. Induction of rat liver DNA alterations by chronic administration of peroxisome proliferators as detected by 32P-postlabeling.
    Randerath E; Randerath K; Reddy R; Danna TF; Rao MS; Reddy JK
    Mutat Res; 1991 Mar; 247(1):65-76. PubMed ID: 2002806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 32P-postlabeling analysis of peroxisome proliferator-DNA adduct formation in rat liver in vivo and hepatocytes in vitro.
    Gupta RC; Goel SK; Earley K; Singh B; Reddy JK
    Carcinogenesis; 1985 Jun; 6(6):933-6. PubMed ID: 4006083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotoxic effects of selected peroxisome proliferators.
    Reisenbichler H; Eckl PM
    Mutat Res; 1993 Apr; 286(2):135-44. PubMed ID: 7681524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrasting hepatocytic peroxisome proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens Wy-14,643 and clofibric acid.
    Marsman DS; Goldsworthy TL; Popp JA
    Carcinogenesis; 1992 Jun; 13(6):1011-7. PubMed ID: 1600604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of pancreatic and testicular tumors in rats treated with ciprofibrate, a peroxisome proliferator.
    Rao MS; Subbarao V
    Cancer Lett; 1995 Nov; 97(2):185-8. PubMed ID: 7497461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid.
    Wilson MW; Lay LT; Chow CK; Tai HH; Robertson LW; Glauert HP
    Arch Toxicol; 1995; 69(7):491-7. PubMed ID: 8526745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased resistance of peroxisome proliferator-induced hepatic lesions to iron overload in rats.
    Rao MS; Subbarao V; Reddy JK
    Cancer Lett; 1986 Jul; 32(1):33-9. PubMed ID: 3742486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of rats with the peroxisome proliferator ciprofibrate results in increased liver NF-kappaB activity.
    Li Y; Leung LK; Glauert HP; Spear BT
    Carcinogenesis; 1996 Nov; 17(11):2305-9. PubMed ID: 8968042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the mechanism of the hepatocarcinogenicity of peroxisome proliferators.
    Nilsson R; Beije B; Préat V; Erixon K; Ramel C
    Chem Biol Interact; 1991; 78(2):235-50. PubMed ID: 2040027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the hepatic responses to the short-term administration of ciprofibrate in several rat strain. Co-induction of microsomal cytochrome P-450 IVA1 and peroxisome proliferation.
    Makowska JM; Anders C; Goldfarb PS; Bonner F; Gibson GG
    Biochem Pharmacol; 1990 Sep; 40(5):1083-93. PubMed ID: 2390105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of peroxisome proliferators on phosphoprotein levels in human and rat hepatic-derived cell lines.
    Passilly P; Jannin B; Latruffe N
    Eur J Biochem; 1995 May; 230(1):316-21. PubMed ID: 7601116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of the concentrations of prostaglandins E2 and F2alpha, and thromboxane B2 in cultured rat hepatocytes treated with the peroxisome proliferator ciprofibrate.
    Leung LK; Glauert HP
    Toxicol Lett; 1996 Jun; 85(3):143-9. PubMed ID: 8644126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Species differences in hepatic peroxisome proliferation, cell replication and transforming growth factor-beta1 gene expression in the rat, Syrian hamster and guinea pig.
    Lake BG; Rumsby PC; Price RJ; Cunninghame ME
    Mutat Res; 2000 Mar; 448(2):213-25. PubMed ID: 10725474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: comparison of WY-14,643 to clofibric acid, nafenopin and LY171883.
    Eacho PI; Lanier TL; Brodhecker CA
    Carcinogenesis; 1991 Sep; 12(9):1557-61. PubMed ID: 1893515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flow cytometric analysis of neoplastic nodules and hepatocellular carcinomas induced by ciprofibrate in the rat.
    Goolsby CL; Rao MS
    Br J Cancer; 1996 Jan; 73(2):197-202. PubMed ID: 8546906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Species differences in the hepatic response to a potent peroxisome proliferator.
    Makowska JM; Bonner FW; Goldfarb PS; Gibson GG
    Biochem Soc Trans; 1989 Dec; 17(6):1072-3. PubMed ID: 2628085
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative induction of cytochrome P450IVA1 and peroxisome proliferation by ciprofibrate in the rat and marmoset.
    Makowska JM; Bonner FW; Gibson GG
    Arch Toxicol; 1991; 65(2):106-13. PubMed ID: 1905530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formation of 8-hydroxydeoxyguanosine in liver DNA of rats following long-term exposure to a peroxisome proliferator.
    Kasai H; Okada Y; Nishimura S; Rao MS; Reddy JK
    Cancer Res; 1989 May; 49(10):2603-5. PubMed ID: 2713844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on eicosanoid concentrations in rat liver.
    Wilson MW; Leung LK; Hong JT; Glauert HP
    Adv Exp Med Biol; 1997; 400A():439-45. PubMed ID: 9547588
    [No Abstract]   [Full Text] [Related]  

  • 20. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats.
    Marsman DS; Cattley RC; Conway JG; Popp JA
    Cancer Res; 1988 Dec; 48(23):6739-44. PubMed ID: 3180084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.